Life Sciences Archive » January, 2026

Life Sciences - January, 2026

271 articles

• 3rd Circ. Preview: Privacy Issues Top Feb. Argument Lineup
• CBD Cos. Say They're Wrong Defendants In Kratom Suit
• Dozens Of Cases Linking Zantac To Cancer Thrown Out
• Drugmakers Ask To Appeal Overarching Conspiracy Claim
• Checking In On Biologics-Related Patent Review Trends
• ThermoLife Asks Justices To Resolve Split Over Sanctions
• Amazon Says Shoppers' Labeling Suit Is Corrupted By AI Errors
• Drug Cos. Want Rethink Of DQ Bid Targeting Ex-Prosecutor  
• 4 Quick Emotional Resets For Lawyers With Conflict Fatigue
• AstraZeneca Beats FMLA Suit After Ex-Worker Went Silent
• J&J, Talc Unit Get Patients' Bankruptcy Fraud Claims Tossed
• Conn. Drug Price Cap Survives Distributor Challenge, For Now
• ITC To Review Medical Imaging Imports For Infringement
• Teva Tries To Spike Paragard Trial Claims, Punitive Damages
• Inspire Medical Leaders Face Suit Over Apnea Device Rollout
• Imported Scooters Not Duty-Free, UK Court Says In Reversal
• Sandoz, Teva Beat Malicious Prosecution Claims, For Now
• Rescheduling Cannabis Marks New Tax Era For Operators
• Navigating Trade Secret Exceptions In Noncompete Bans
• Playing Tennis Makes Me A Better Lawyer
• Dispensaries Sue Hawaii Over Criminalizing Hemp Products
• SpaceX Eyes IPO At $1.5 Trillion Value, Plus More Rumors
• Trade Secret Filings Hit Record High In 2025, Report Finds
• Biogen Can't Escape Amended Antitrust Suit Over MS Drug
• Teva Allowed New Mifepristone Claim But Not New Defendant
• Tax Court Rejects Aventis' Securitizing Debt Assets
• After Fed. Circ. Remand, PTAB Again Backs Bausch Patent
• New Squires Order Allows 4 Patent Reviews, Denies 25 Others
• Expect Major Shifts In Patent And Trademark Policy This Year
• Attys Get $2.5M In $7.5M Preterm-Birth Drug Settlement
• BlackRock, Eclipse Lead Cellares' $257M Funding Round
• Crowell & Moring Adds Tech Firm IP Atty In Southern Calif.
• ArentFox Schiff Launches Longevity Industry Group
• LegitScript's Counterclaims Against PharmacyChecker Tossed
• Class Actions At The Circuit Courts: January Lessons
• Judges On AI: How Judicial Use Informs Guardrails
• Robins Kaplan Takes Aim At Benicar MDL Fees Suit In NJ
• Generics Makers Want Hospital Drug Data In Price-Fixing MDL
• 3rd Circ. Appears Skeptical Of Quest's Early Win In 401(k) Suit
• Ohio PBM Suit Belongs In Federal Court, 6th Circ. Rules
• Lasik Provider Can't Shake Wiretap Claims In Tracking Row
• BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial
• Kelley Drye Adds Ex-23andMe, Facebook Privacy Pros
• Medtronic Rival's VP Says Docs Praised Device But Didn't Buy
• Law360 Seeks Members For Its 2026 Editorial Boards
• Biotech Fundraising A Good Sign For Public Markets
• CBP's Medical Care Oversight Needs Improvement, GAO Says
• White House Pushed To Back PTAB Rule Change Proposal
• Investors Say Teva Can't Get Early Win In Price-Fixing Suit
• Mylan's Sanofi Insulin Suit Mostly Survives Dismissal Bid
• What US Cos. Must Know To Comply With Italy's AI Law
• Ag Bill Wording Presents Existential Threat To Hemp Industry
• Generics Makers Fight Cert. In Cholesterol Drug Pricing MDL
• Masimo Chafes Against Apple's Bid To Duck $634M IP Verdict
• Ill. Judge Trims False Ad Suit Over Abbott Formula
• Novo Nordisk Faces Class Claims Over GLP-1 Patent Tactics
• O'Melveny Brings On Proskauer M&A Pro In California
• Zenas BioPharma Slams Investor's Revamped Fraud Claim
• Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief
• Catching Up With Delaware's Chancery Court
• 5 Drug Pricing Policy Developments To Watch In 2026
• DC Circ. Revives Terrorism Liability Suit Against Pharma Cos.
• Paraquat, J&J Talc Litigation Headline Philly's 2026 Mass Torts
• Heart Valve Deal Was Blocked Over Innovation Concerns
• Cartiva Hid Toe Implant Safety Info, Pa. Woman's Suit Claims
• $200M Sun, Taro Generics Deal Gets Final OK
• CytoDyn CEO Gets 30-Month Sentence For Lying To Investors
• New Zynex Leaders Acknowledge Fraud Arrests Of Ex-Execs
• Patent Applicants Must Get Biologics Enablement Right
• 3rd Circ. Preview: Citizens Bank, Quest Fight Appeals In Jan.
• Law School's Missed Lessons: How To Start A Law Firm
• Reforms, $737.5K Fee Proposed To End Del. Skin Tech Suit
• Guardant Can Try Again To Nix Patent Tied To $83M Verdict
• Taxation With Representation: Vinge, A&O Shearman, Cassels
• Patent Office Beats La Jolla Pharma's Application Denial Suit
• House Report Claims Evidence of CVS Antitrust Violations
• Supplement Cos. Challenge FDA Health Claim Denials
• Merck Can't Get Fed. Circ. To Reconsider Axing MS Drug Patents
• Fed. Circ. Patent Decisions In 2025: An Empirical Review
• Regulatory Uncertainty Ahead For Organ Transplant System
• Hologic Faces Del. Class Suit Over $18.3B Sale Disclosures
• Key False Claims Act Trends From The Last Year
• 3rd Circ. Says Medical Pot Contract May Violate Federal Law
• AI Diagnostics Co.'s Patent Claims Don't Pass Alice Test
• Simpson Thacher Adds Quinn Emanuel Atty To New SF Office
• It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs
• Medical Cannabis Co. Says Data Breach Didn't Lead To Injury
• Hosting Exchange Students Makes Me A Better Lawyer
• Investors Drop LA Law Firm From Bioscience Fraud Suit
• Holmes Seeks Trump Clemency For Theranos Fraud Sentence
• CVS, UnitedHealth, Express Scripts Duck PBM Antitrust Suit
• Bristol-Myers' Worker Arbitration Push Scrutinized On Appeal
• Medtronic 'Blocked' Surgical Device Competition, Jury Told
• Texas AG Launches Investigation Into Vaccine Incentives
• Novartis Gets Win On Entresto Patent Tied To Earlier Ruling
• FDA's 2025 Enforcement Scorecard Highlights Data Focus
• Allergan Says Fed. Circ.'s Ax Of $39M Win Misread Record
• Teva's Inconsistent Args In IUD Trial 'Troubling,' Judge Says
• FTC Mulling Deal With Express Scripts In PBM Case
• How A 1947 Tugboat Ruling May Shape Work Product In AI Era
• Fla. Dispensary Exposed Patient Data Via Google, Suit Says
• Justices To Clarify What's Fair Game With 'Skinny Labels'
• Orrick Expands IP Team With Cadwalader, Kirkland Litigators
• Dentsply Can't Shed Investors' Aligner Injury Cover-Up Suit
• Law360 Names Firms Of The Year
• Fed. Circ. Revives Inventor's Spinal Patent Case Against DePuy
• Philips CPAP Cancer Suit Sent Back To Kentucky
• NY Judge Orders SD To Pause Action Against Abortion Ads
• Ex-Med Spa Workers Say Poaching Claims Can't Stay In Conn.
• Johnson & Johnson Faces 2nd Talc Trial In Philadelphia
• Va. Lawmakers Eye Psilocybin Regulation Pending FDA Action
• CorMedix Investors Seek First OK Of Governance Reform Deal
• McCarter & English Knocks Down Biotech Malpractice Appeal
• Navigating Privilege Law Patchwork In Dual-Purpose Comms
• Catching Up With Delaware's Chancery Court
• Law360 Names Practice Groups Of The Year
• DOJ Reports Historic $6.8B False Claims Act Haul In 2025
• PBMs Seek Exit From Philly's Suit Over Opioid Crisis
• SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
• Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit
• 6th Circ. Revives Biomed Co. Investor's Suit Over Stock Sale
• NuVasive Loses Appeal Over Ex-Exec's Ties To Competitor
• Acadia Investors Get Initial OK For $179M Settlement
• How AI Drafting Should Transform Patent Filing Strategies
• 5 Advertising Law Trends That Will Shape 2026
• Pomerantz To Lead Biohaven Investors' FDA Approval Suit
• Taxation With Representation: Stibbe, A&O Shearman, Latham
• J&J Largely Loses Bid To Toss Former Atty's NJ Bias Suit
• Cannabis Industry Faces An Inflection Point This Year
• Supreme Court Takes On Hikma's 'Skinny Label' Patent Case
• Bioness $110M Sale Suit Heads to $8.9M Deal
• SEC Says Healthcare Exec Misspent $10.6M In Investor Funds
• Ex-CEO Of COVID Vax Maker Accused Of Insider Trading
• Trial 'No Longer Warranted' After Judge's Stelara Reversal
• Simpson Thacher Guides New Mountain's $1.2B Fund Close
• Chancery Tosses Vividion IP Suit Over $2B Bayer Deal
• CVS Ducks Antitrust But Not Biz Interference Claim At 5th Circ.
• Rite Aid Trusts Can Access Health Data To Pursue Tort Claims
• Crowell Lands Buchalter Practice Group Co-Chair In Calif.
• Fly-Fishing Makes Me A Better Lawyer
• White & Case Adds Life Sciences Team From A&O Shearman
• 4 Ways GCs Can Manage Growing Service Of Process Volume
• Carlyle Among Bidders For Lukoil Assets, Plus More Rumors
• 3 Firms Advise On Boston Scientific's $14.5B Penumbra Deal
• Dover Launches RICO Suit Over Skyrocketing Insulin Prices
• Pharmacy Wields Antitrust Law In Challenge To GLP-1 Giants
• 6th Circ. Skips Rethink, But Still Spars Over Indirect Buyer Bar
• Exasperated Judge Won't Expand Opioid Film Injunction
• NJ Judge Orders Mediation In Merck-Cencora Indemnity Fight
• The Law Firm Merger Diaries: Forming Measurable Ties
• Biotech Co. CytoDyn In Talks To End Investor Class Action
• AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny
• Wholesaler Admits To $2.5M Opioid Diversion Scheme
• ITC To Probe Samsung's Oura Smart Ring Patent Case
• GOP Senators Say Patients Must See Docs For Abortion Meds
• Pharma Co. Consultant Charged With Insider Trading
• Cannabis Co. Says Rivals Infringe Distillation Patents
• La. Moves To Extradite Calif. Doc Over Abortion Pill Trafficking
• Medical Device Co. Faces New Derivative Suit In Delaware
• US Patent Applications Plunge After Years Of Growth
• Squires Institutes 8 Patent Reviews, Rebuffs 47 Petitions
• FDA's AI Deployment Brings New Potential And Risks
• 3 Key Takeaways From Planned Rescheduling Of Cannabis
• 6 Issues That May Follow The 340B Rebate Pilot Challenge
• 5 E-Discovery Predictions For 2026 And Beyond
• Beasley Allen Talc Work Sends 'Bad Signal,' J&J Says
• Express Scripts Can't Impel FTC Atty Views On Insulin Makers
• J&J Wins Partial Reversal Of $1B Merger Milestone Loss
• Streamlining Product Liability MDLs With AI And Rule 16.1
• CareFirst Opposes J&J's Bid To Revisit Stelara Antitrust Case
• The Curious, Very Long Delay In A Pioneering Drug Prices Suit
• Del. Jurist Cites 'Troubling' Questions In Cashout Suit
• Terumo Plaintiff Settles, Drops Cancer Case Before Trial
• Del. Court Blocks Presuit Damages On Agilent Patent
• Feds To Drop Appeal In 340B Rebate Pilot Challenge
• Business Considerations Amid Hemp Product Policy Change
• Sidley-Led Smith & Nephew Inks $450M Orthopaedics Deal
• Judges On AI: How Courts Can Boost Access To Justice
• Medicine Biz Mirador Wraps $250M Funding Round
• Justices Want SG Input On Arthritis Drug Competition Fight
• No High Court Review For California Opioid 'Nuisance' Suit
• Justices Won't Weigh Collective Cert. Process In Eli Lilly Case
• Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims
• Squires Sets Precedent, Guidance On Discretionary Denials
• Fed. Circ. In November: Looking For Patent 'Blaze Marks'
• 2025's Most Notable State AG Activity By The Numbers
• Biopharma Co. Secures D&O Coverage For Shareholder Suit
• Veterinary Group Says DOJ Accreditation Points Irrelevant
• Judge Denies 'Fatally Untimely' Bid For New Poaching Trial
• Judge Blocks Edwards' $945M Heart Valve Deal
• 4 Argument Sessions That Benefits Attys Should Watch In Jan.
• The Case For Emulating, Not Dividing, The Ninth Circuit
• How New Judges Can Quell Patent Litigation Fears
• Ex-Prosecutor OK For Drug Pricing MDL, Special Master Says
• Biotech AirNexis Wraps Funding Round With $200M Raised
• NC Biz Court Bulletin: Trade Secrets Row, A Patient Data Deal
• IDEXX Software Defect Blamed For At Least 40 Dog Deaths
• Paul Hastings-Led Oncology Firm Prices Upsized $318M IPO
• Walgreens Gets $392K Sanction Against Blue Cross Insurers
• Apple Beats Antitrust Suit Over Heart Rate Data At 9th Circ.
• FTC Battles Edwards On Eve Of Heart Valve Merger Deadline
• How Rule 16.1 Streamlines And Validates Mass Tort Litigation
• AbbVie Sues Over Bids To Market Generic Migraine Drugs
• How 11th Circ.'s Zafirov Decision Could Upend Qui Tam Cases
• Organ Procurer Says CMS Rule Will Toss Industry Into Chaos
• ITC To Investigate Smartwatch Giants Over Fall Detection IP
• Key Trends For Life Sciences Cos. To Watch In 2026
• 2 Firms Guide Eli Lilly's $1.2B Ventyx Biosciences Acquisition
• Cooley Adds Longtime Sidley Healthcare Attorney In DC
• Leason Ellis Hires 9 Life Sciences Pros From Haley Guiliano
• Cooley-Led Eir Partners Wraps $1B Health Tech Fund
• Trump Admin Can't Undo Block On Drug Rebate Program
• Husch Blackwell Expands With 18-Person Immigration Team
• Muay Thai Makes Me A Better Lawyer
• Biotech Co. Says HHS Infringed Patent With Moderna Vax Deal
• Amazon Seeks To Halt Supplement Suit As FDA Nixes Rule
• The Next Pressure Point In Digital Health: Informed Consent
• Law School's Missed Lessons: Intentional Career-Building
• Fed. Circ. Suggests Sepsis Test IP Needs Claim Construction
• Potomac Law Adds Former DOJ, HHS Civil Rights Atty
• Kaplan Fox Remains Lead In Securities Suit After Ex-Client DQ
• Detroit Pension Fund Wins 'Close' Call To Lead Investor Suit
• Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties
• Cigna Accused Of Rigging Market For Life-Saving Drugs
• FDA To Ease Regulation Of Wearables, Decision Software
• 1st Circ. Questions Feds' Mootness Claim In NIH Grant Suits
• Trending At The PTAB: The Policies That Are Redefining IPR
• 4 Trends Shaping Drug And Medical Device Law For 2026
• RFK Jr. Can't Avoid Medical Groups' Challenge To Vax Policy
• NJ Judge Signals Green Light To Revive J&J Unit's Libel Suit
• Public Health Atty Talks Botulism, Infants And FDA Staffing
• Drugmakers Fight Multifront Legal Battles Over GLP-1s
• Wyo. High Court Strikes Down 2 Laws Restricting Abortion
• Ill. Judge Trims Most Of Walgreens Shareholder Suit
• Healthcare Litigator Moves Practice To Troutman In Philly
• Federal Prosecutor Rejoins King & Spalding In Atlanta
• Top Personal Injury, Medical Malpractice Cases Of 2025
• 1st Circ. Upholds Block On Trump Admin NIH Funding Cuts
• Fed. Circ. Examines Timing Of $452M Trade Secrets Suit
• Express Scripts Wants FTC Atty Views On Insulin Prices
• Cancer Biotech Co. Eyes $182M IPO
• Trending At The PTAB: The Journey Of IPR Institution In 2025
• Aetna Drug Price-Fixing Suit Against Pharma Cos. Paused
• 3rd Circ. Won't Rethink Tax On Interest In $191M Pharma Deal
• Health Officials Roll Back Child Vaccine Recommendations
• A Meaningful Shift In FDA's Biosimilarity Analysis
• Ind. Sues Eli Lilly Over 'Grossly Inflated' Insulin Prices
• Trump Backs Biden's Medicare Drug Price Law At High Court
• Thesis Supplements Illegally Sold As ADHD Drugs, Suit Says
• Paul Hastings Adds Hogan Lovells Duo To Life Sciences Team
• Catching Up With Delaware's Chancery Court
• IRS Floats Updates To Fee Paid By Brand Drugmakers
• Drug Pricing Battles To Watch In 2026
• Product Liability Cases To Watch In 2026
• Patent Litigation Trends To Watch In 2026
• Antitrust Cases Ahead: Live Nation, Middleman On Trial
• Trade Secret Trends To Watch In 2026
• NC Legislation To Watch In 2026: Healthcare Funding In Focus
• California Cases To Watch In 2026
• Patent Policy To Watch In 2026
• North Carolina Cases To Watch In 2026
• New Jersey Cases To Watch In 2026
• SnapChat, Pork And Big Prosecutions: Trials To Watch In 2026
• What To Watch In Massachusetts Courts In 2026
• Pennsylvania Cases To Watch In 2026
• Patent Cases To Watch In 2026
• The High-Stakes Healthcare AI Battles To Watch In 2026
• 4 Developments That Defined The 2025 Ethics Landscape
• 4 High Court Cases To Watch This Spring
• Blue Slip Fight Looms Over Trump's 2026 Judicial Outlook
• BigLaw Leaders Tackle Growth, AI, Remote Work In New Year